| To analyze the clinical feature of patients with Candida infection and their resistance to antifungal drugs, and provide evidence for reasonable clinical medication. Methods The related clinical data were collected from hospitalized patients with chronic liver disease in Beijing You’an Hospital, Capital Medical University from March 1st, 2017 to March 1st, 2018, and the drug sensitivity of the detected Candida strains was tested in vitro. Results Among the 106 cases of Candida infection, Candida albicans was the main isolates and the infection rate reached 43.4%. Candida tropicalis was the most common non-Candida albicans with an infection rate of 19.8%. The resistance rate of Candida albicans to five common antifungal drugs was relatively lower, while the maximal resistance was achieved against amphotericin B, accounting for 8.7%. The resistance rate of Candida albicans to fluconazole and voriconazole was significantly lower than that of non-Candida albicans, with statistically significant difference (P＜0.05). There was no statistically significant difference in the resistance rate of all strains to itraconazole and amphotericin B (P＞0.05), and the resistance rate of all strains to 5-fluorocytosine was relatively low, with no statistically significant difference (P＞0.05). Conclusions Candida albicans is still predominant Candida infection in patients with chronic liver disease. The resistance rate of Candida albicans to commonly used antifungal drugs is relatively low. In clinical practice, drugs should be reasonably selected based on the drug sensitivity results. |